Import from '@/components/mdx'

Nurtec ODT and Bupropion: What the Drug Interaction Actually Means for You

The Short Answer on Taking Nurtec ODT with Bupropion

These two drugs can be prescribed together, and many women already take them simultaneously. The combination is not contraindicated. The clinical caution is more nuanced than a simple yes-or-no: bupropion's inhibition of CYP2D6 does not directly affect rimegepant's primary metabolic pathway, but bupropion does carry a dose-dependent seizure risk that requires awareness, and rimegepant's own pharmacokinetic profile introduces a separate consideration around CYP3A4 inhibitors and P-glycoprotein.

Why This Combination Is So Common in Women

Migraine affects approximately three times as many women as men, and the peak prevalence overlaps almost exactly with the reproductive years and perimenopause. Depression and anxiety are also more prevalent in women with migraine, with comorbid depression occurring in roughly 40% of people with chronic migraine. Bupropion (sold as Wellbutrin, Aplenzin, and Forfivo XL) is frequently chosen in this group because, unlike SSRIs and SNRIs, it does not cause sexual dysfunction and may support weight management, both of which matter to women navigating hormonal transitions.

So the clinical reality is straightforward: a perimenopausal woman with worsening menstrual migraine and new-onset depression may find herself prescribed rimegepant for migraine and bupropion for depression or for smoking cessation. Her prescribers need to understand the pharmacology of both.

How Rimegepant Works: The CGRP Mechanism

Rimegepant is a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist. It blocks the vasodilatory and pain-signaling actions of CGRP at the receptor level, which is distinct from how older gepants like ubrogepant work only acutely. The FDA-approved labeling for rimegepant covers both acute treatment (75 mg ODT as needed) and preventive use (75 mg ODT every other day).

How Rimegepant Is Metabolized

This is the pharmacokinetic detail that matters most for understanding the bupropion interaction, or more precisely, why the interaction is less severe than it might first appear.

Rimegepant is primarily metabolized by CYP3A4, with minor contribution from CYP2C9. It is also a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). Bupropion's primary inhibitory activity is on CYP2D6, not CYP3A4. This mismatch is the core reason the interaction is categorized as moderate rather than severe: bupropion does not substantially block the enzyme that clears rimegepant from your body.

The FDA label for rimegepant is explicit about which inhibitors require dose adjustment: strong or moderate CYP3A4 inhibitors (such as ketoconazole or fluconazole) and P-gp inhibitors (such as cyclosporine) warrant dose reduction or avoidance. Bupropion falls into neither category.

What CYP2D6 Inhibition by Bupropion Actually Does

Bupropion and its active metabolite hydroxybupropion are potent inhibitors of CYP2D6. This matters when rimegepant is co-prescribed with other drugs that ARE CYP2D6 substrates, such as tricyclic antidepressants, certain beta-blockers used for migraine prevention (metoprolol, propranolol), codeine, or tramadol. If you are on rimegepant plus bupropion PLUS propranolol for migraine prevention, the propranolol is the drug whose exposure rises, not rimegepant.

Bupropion's Seizure Risk: The Clinically Relevant Concern

Bupropion carries a well-established dose-dependent risk of seizures. The FDA label for bupropion hydrochloride extended-release states that the incidence of seizure is approximately 0.1% at doses up to 300 mg/day and rises to approximately 0.4% at 400 mg/day. Exceeding recommended doses or using immediate-release formulations erratically substantially increases this risk.

Rimegepant does not appear to lower seizure threshold independently based on available data. The concern with this combination is not a pharmacodynamic combination that raises seizure risk above bupropion's baseline. The concern is more operational: women who take bupropion should avoid any other medications or supplements that also lower seizure threshold, and they should report any neurological symptoms promptly.

Women-Specific Factors That Affect Seizure Risk with Bupropion

Several factors more common in women can interact with bupropion's seizure liability:

• Eating disorders. Bupropion carries a black box warning against use in people with current or history of bulimia or anorexia nervosa because of a markedly elevated seizure risk in this population. Women are diagnosed with eating disorders at significantly higher rates than men.
• Electrolyte disturbances. Conditions that cause hyponatremia or hypokalemia (including PCOS-related metabolic dysfunction, excessive use of diuretics, or perimenopausal changes in aldosterone regulation) lower seizure threshold.
• Hormonal fluctuations. Estrogen has pro-convulsant properties at certain concentrations, while progesterone metabolites (particularly allopregnanolone) are generally anti-convulsant. The rapid estrogen withdrawal that occurs perimenstrually or during perimenopause may modestly affect seizure susceptibility. This is studied most in women with catamenial epilepsy, but the physiological principle applies to any medication with seizure risk.

The P-Glycoprotein Angle: Why Your GI Medications Matter Too

Rimegepant is a P-gp substrate. Strong P-gp inhibitors increase rimegepant exposure by reducing its efflux from gut enterocytes, which raises plasma levels. Bupropion is not a clinically significant P-gp inhibitor, so this pathway is not a concern specific to the rimegepant-bupropion combination. However, if you add a P-gp inhibitor such as clarithromycin or verapamil to a regimen that already includes both rimegepant and bupropion, rimegepant exposure may rise meaningfully.

The rimegepant prescribing information recommends avoiding co-administration with strong CYP3A4 inhibitors and recommends a single dose of rimegepant (avoid repeat dosing within 48 hours) when a moderate CYP3A4 inhibitor or a P-gp inhibitor is unavoidable.

Migraine, Hormones, and Why Life Stage Changes Everything

The following framework is not standard in most drug-interaction resources, which are written from a sex-neutral lens. WomanRx is presenting it here because hormonal status changes both migraine biology and the choice of antidepressant in ways that affect how you weigh this combination.

Reproductive Years and Menstrual Migraine

Menstrual migraine, defined as migraine occurring within two days before to three days after the onset of menstruation, is driven primarily by the sharp drop in estrogen that triggers the perimenstrual window. ACOG Practice Bulletin No. 228 recognizes hormonal fluctuation as a primary migraine trigger in women of reproductive age. Rimegepant's every-other-day preventive dosing schedule is specifically useful here because it can be timed around the anticipated perimenstrual window.

Bupropion is not a recognized treatment for menstrual migraine. If you are using it for depression or smoking cessation, it does not add to migraine prevention. The two drugs are addressing different problems, and their co-prescription is simply that: two medications for two conditions.

Trying to Conceive and Pregnancy

This combination requires a direct conversation with your OB-GYN or maternal-fetal medicine specialist before you begin trying to conceive.

Rimegepant: human pregnancy data are limited. Animal studies showed adverse developmental outcomes at exposures above the human therapeutic dose, according to the rimegepant FDA label. The drug should be discontinued before conception is attempted. There is no established safe dose in pregnancy.

Bupropion: classified as Pregnancy Category C under the old FDA system. Observational data have suggested a possible association between first-trimester bupropion exposure and cardiac septal defects, though the absolute risk remains low and findings have been inconsistent across studies. The benefit-risk decision is individualized, particularly for women with significant depression who may face higher risks from untreated illness than from medication exposure.

If you are on rimegepant preventively and want to conceive, discontinue it first. For acute migraine in pregnancy, acetaminophen remains the first-line option in the first trimester, with careful specialist guidance for refractory cases.

Lactation

Rimegepant: the FDA label advises against use during breastfeeding because there are no data on the presence of rimegepant in human milk, its effects on the breastfed infant, or its effects on milk production.

Bupropion: present in breast milk at low levels. The LactMed database states that most studies show low levels in infant serum and that short-term use appears to be relatively low risk. One case report raised concern about possible seizure in an exposed infant, though causality was not established. Most lactation medicine specialists consider bupropion acceptable with monitoring.

Given that rimegepant cannot be recommended during breastfeeding, women who are postpartum and breastfeeding should discuss alternative acute migraine strategies, such as sumatriptan, which has substantially more lactation safety data.

Perimenopause

This is the life stage where the rimegepant-bupropion combination is most common and, arguably, most clinically complex. Migraine often worsens during perimenopause due to increasing hormonal variability. Depression and anxiety also peak during this transition. The Menopause Society (formerly NAMS) 2023 position statement notes that mood symptoms in perimenopause are frequently underdiagnosed and undertreated.

Bupropion is sometimes chosen over SSRIs in perimenopausal women because it avoids sexual side effects at a time when sexual function is already threatened by declining estrogen, and because it does not cause weight gain. The trade-off is the seizure risk, which your prescriber must weigh against bupropion's benefits.

Rimegepant's every-other-day preventive schedule may be particularly useful in perimenopause because irregular cycles make timing triptan mini-prophylaxis difficult. A standing every-other-day regimen covers erratic hormonal fluctuation more reliably.

Monitoring and Practical Steps for Women on Both Drugs

The absence of a severe or contraindicated interaction does not mean monitoring is optional. A reasonable approach for a woman on both rimegepant and bupropion includes the following:

At the time of co-prescribing:

• Confirm bupropion dose is at or below 300 mg/day if possible, to keep seizure risk at the lower end of the documented range.
• Screen for eating disorder history, as this is an absolute contraindication to bupropion regardless of rimegepant.
• Document any other CYP2D6-substrate drugs in the regimen (propranolol, metoprolol, amitriptyline, codeine) because those are what bupropion will affect, not rimegepant itself.
• Ask about supplements. St. John's Wort is a CYP3A4 inducer and would lower rimegepant levels. It also carries serotonin-related interaction concerns with antidepressants.

Ongoing:

• Report any new-onset seizure activity, unusual neurological symptoms, or changes in migraine pattern.
• If a CYP3A4 inhibitor (such as fluconazole for a yeast infection, which is extremely common in women on antibiotics) is added, remind your provider you are also taking rimegepant, as a short course of fluconazole is a moderate CYP3A4 inhibitor and could transiently raise rimegepant exposure.
• Track migraine frequency. Rimegepant for prevention should reduce monthly migraine days by at least 1 to 2 days within 8 to 12 weeks based on the BHV3000-305 trial, which showed a statistically significant reduction in mean monthly migraine days versus placebo (4.3 vs 3.5 days, p=0.0099) over 12 weeks.

Who This Combination Is Right For, and Who Should Reconsider

More likely to be appropriate:

• Perimenopausal women with worsening migraine frequency and comorbid depressive symptoms who want to avoid SSRI-associated weight gain or sexual dysfunction.
• Women with PCOS who have migraine and depression, where weight-neutral antidepressant choice matters.
• Women who have tried triptans and found them ineffective or who have cardiovascular risk factors precluding triptan use, making rimegepant a preferred acute agent.
• Women using bupropion for smoking cessation and who need acute migraine treatment during the cessation attempt.

Requires careful review or alternative:

• Women with a personal or family history of seizures. Bupropion is relatively contraindicated here regardless of rimegepant.
• Women with current or prior bulimia or anorexia. The bupropion black box warning applies.
• Women who are pregnant or actively breastfeeding. Rimegepant should be stopped; bupropion requires an individualized discussion.
• Women already taking strong CYP3A4 inhibitors chronically (such as certain HIV antiretrovirals or antifungals), where rimegepant exposure may already be elevated before bupropion is added.
• Women on propranolol or metoprolol for migraine prevention, where bupropion's CYP2D6 inhibition will increase beta-blocker exposure and may require a propranolol or metoprolol dose reduction.

Evidence Gaps: What We Do Not Know

Women have been systematically underrepresented in pharmacokinetic drug-interaction studies. The data on rimegepant-bupropion co-administration comes from mechanistic understanding of the metabolic pathways, not from a prospective clinical trial of this specific combination in women. The rimegepant clinical development program enrolled predominantly women (approximately 80% of participants in the BHV3000-305 prevention trial), which is an improvement over older migraine drug trials, but the interaction sub-studies were not powered to detect sex-specific differences in CYP-mediated interactions.

No published study has specifically examined how the perimenopausal hormonal milieu affects the pharmacokinetics of either rimegepant or bupropion in the same patient. Estrogen influences CYP3A4 expression, and progesterone affects drug metabolism in ways that are not yet fully quantified across the menstrual cycle. This is an area where clinical guidance is extrapolated from first principles, not directly studied in perimenopausal women.

A Note on the Serotonin-Adjacent Question

Some women ask whether combining rimegepant with bupropion poses any serotonin syndrome risk. Rimegepant has no serotonergic mechanism. Bupropion's primary action is on dopamine and norepinephrine reuptake inhibition, with weak serotonin effects. Serotonin syndrome with bupropion is most associated with its combination with MAOIs or with serotonergic agents like SSRIs. The rimegepant-bupropion combination does not create a meaningful serotonin syndrome risk based on their pharmacodynamic profiles, per the FDA bupropion labeling.

What to Tell Your Prescriber

Many women see a neurologist for migraine and a separate provider for depression or smoking cessation. Medication reconciliation gaps are real. Before your next appointment, bring a complete medication list that includes:

• The exact bupropion formulation (immediate-release, sustained-release, or extended-release) and dose.
• How often you take rimegepant and whether you use it acutely, preventively, or both.
• Any antifungals, antibiotics (particularly macrolides), or herbal supplements taken regularly or intermittently.
• Any propranolol, metoprolol, or amitriptyline, because those are the CYP2D6 substrates that bupropion will affect in your regimen.

The American Headache Society's 2024 guidance on CGRP-pathway therapies states that drug-drug interactions with gepants are "primarily driven by CYP3A4 and P-gp pathways" and that clinicians should review the full medication list for inhibitors or inducers of those pathways before prescribing rimegepant. Bupropion does not appear on the list of problematic co-medications in that guidance, which is consistent with the mechanistic analysis above.

If you are on bupropion 450 mg/day (the maximum approved dose), you are already at the upper boundary of seizure risk. Adding any new neurologically active drug at that dose level warrants a conversation with a single prescriber who can see the full picture.